Pharmacogenetics of anti-HIV drugs

被引：54

作者：

Telenti, A. ^{[1
]}

Zanger, U. M. ^{[2
,3
]}

机构：

[1] Univ Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland

[2] Univ Tubingen, D-72074 Tubingen, Germany

[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2008年 / 48卷

关键词：

protease inhibitors; non-nucleoside reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; HIV susceptibility; ADME proteins;

D O I：

10.1146/annurev.pharmtox.48.113006.094753

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.

引用

页码：227 / 256

页数：30

共 161 条

[121] Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals [J].

Rotger, M. ;

Tegude, H. ;

Colombo, S. ;

Cavassini, M. ;

Furrer, H. ;

Decosterd, L. ;

Blievernicht, J. ;

Saussele, T. ;

Guenthard, H. F. ;

Schwab, M. ;

Eichelbaum, M. ;

Telenti, A. ;

Zanger, U. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :557-566

[122] Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia [J].

Rotger, M ;

Taffé, P ;

Bleiber, G ;

Günthard, HF ;

Furrer, H ;

Vernazza, P ;

Drechsler, H ;

Bernasconi, E ;

Rickenbach, M ;

Telenti, A .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (08) :1381-1386

[123]

ROTGER M, 2005, INT C ANT AG CHEM 45

[124]

ROTGER M, 2007, IN PRESS PHARMACOGEN

[125] Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents [J].

Rotger M. ;

Csajka C. ;

Telenti A. .

Current HIV/AIDS Reports, 2006, 3 (3) :118-125

[126] An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children [J].

Saitoh, A ;

Singh, KK ;

Powell, CA ;

Fenton, T ;

Fletcher, CV ;

Brundage, R ;

Starr, S ;

Spector, SA .

AIDS, 2005, 19 (04) :371-380

[127] Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [J].

Samson, M ;

Libert, F ;

Doranz, BJ ;

Rucker, J ;

Liesnard, C ;

Farber, CM ;

Saragosti, S ;

Lapoumeroulie, C ;

Cognaux, J ;

Forceille, C ;

Muyldermans, G ;

Verhofstede, C ;

Burtonboy, G ;

Georges, M ;

Imai, T ;

Rana, S ;

Yi, YJ ;

Smyth, RJ ;

Collman, RG ;

Doms, RW ;

Vassart, G ;

Parmentier, M .

NATURE, 1996, 382 (6593) :722-725

[128] DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS [J].

SCHINKEL, AH ;

SMIT, JJM ;

VANTELLINGEN, O ;

BEIJNEN, JH ;

WAGENAAR, E ;

VANDEEMTER, L ;

MOL, CAAM ;

VANDERVALK, MA ;

ROBANUSMAANDAG, EC ;

TERIELE, HPJ ;

BERNS, AJM ;

BORST, P .

CELL, 1994, 77 (04) :491-502

[129]

Schneider I, 2000, US FOR SERV RMRS-P, V4, P164

[130] Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection [J].

Shaikh, S ;

Ta, C ;

Basham, AA ;

Mansour, S .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (01) :143-145

← 8 9 10 11 12 13 14 15 16 17 →